Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 7/20 | 0.52 |
| ▸ | DRD2 | P14416 | 6/20 | 0.49 |
| ▸ | DRD3 | P35462 | 5/20 | 0.49 |
| ▸ | HTR2A | P28223 | 4/20 | 0.49 |
| ▸ | DRD1 | P21728 | 2/20 | 0.49 |
| ▸ | DRD5 | P21918 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lesopitron SCHEMBL9201343 | 0.99 | HTR1A (0.51) | HTR1ADRD2DRD3HTR2ADRD1 | |
| Lesopitron SCHEMBL1822413 | 0.99 | HTR1A (0.51) | HTR1ADRD2DRD3HTR2ADRD1 | |
| SCHEMBL13532701 | 0.90 | SIGMAR1 (0.44) | HTR1ADRD2DRD3HTR2ADRD1 | |
| SCHEMBL13532676 | 0.87 | SIGMAR1 (0.56) | HTR1ADRD2CYP1A2 | |
| SCHEMBL8108166 | 0.87 | SIGMAR1 (0.41) | HTR1ADRD2HTR2ACYP1A2 | |
| SCHEMBL13532685 | 0.87 | SIGMAR1 (0.41) | HTR1ADRD2DRD3HTR2ADRD1 | |
| SCHEMBL8419526 | 0.85 | MEN1 (0.52) | HTR1ADRD2DRD3HTR2ADRD1 | |
| SCHEMBL8419573 | 0.85 | HTR1A (0.53) | HTR1ADRD2DRD3HTR2ADRD1 | |
| SCHEMBL8416456 | 0.84 | HTR1A (0.52) | HTR1ADRD2DRD3HTR2ADRD1 | |
| SCHEMBL8416310 | 0.84 | HTR1A (0.59) | HTR1ADRD2DRD3HTR2ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-4447949-A1 | PHENYLETHYLIDENEHYDRAZINE DIMERS AND METHODS OF USING SAME | Neurawell Therapeutics (US) | 2024-10-23 | — | — | EP | claimed |
| EP-3706762-B1 | N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO | UNIV EMORY (US) | 2024-10-16 | — | — | EP | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| WO-2023114453-A1 | PHENYLETHYLIDENEHYDRAZINE DIMERS AND METHODS OF USING SAME | Neurawell Therapeutics (US) | 2023-06-22 | — | — | WO | claimed |
| US-20220273600-A1 | LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2022-09-01 | — | — | US | claimed |
| WO-2022165382-A1 | PHENYLETHYLIDENEHYDRAZINE COMBINATION THERAPIES | Neurawell Therapeutics (US) | 2022-08-04 | — | — | WO | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| EP-0624585-B1 | Process for the preparation of 2-(4-(4-(4-chloro-1-pyrazolyl)butyl)1-piperazinyl)pyrimidine | ESTEVE LABOR DR (ES) | 1999-08-18 | — | — | EP | claimed |
| WO-1999013879-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A MONOAMINE OXYDASE INHIBITOR AND THEIR USE IN THERAPY | SANOFI-SYNTHELABO (FR) | 1999-03-25 | — | — | WO | claimed |
| WO-1998042344-A1 | PHARMACEUTICAL COMPOSITION | R. P. SCHERER LIMITED (GB) | 1998-10-01 | — | — | WO | claimed |
| WO-1996038439-A1 | NOVEL POLYMORPHS OF LESOPITRON DICHLOROHYDRATE AND ITS HYDRATED FORMS, PREPARATION METHODS AND COMPOSITIONS CONTAINING THEM | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1996-12-05 | — | — | WO | claimed |
| EP-0502786-B1 | Process for the preparation of aryl(or heteroaryl)-piperazin-1-butyl-azole derivatives | ESTEVE LABOR DR (ES) | 1996-04-24 | — | — | EP | claimed |
| EP-0497658-B1 | Use of (omega-(4-(2-pyrimidinyl)-1-piperazinyl)-alkyl)1H-azole derivatives for the preparation of medicines for the treatment of troubles of the capability of knowing functions | ESTEVE LABOR DR (ES) | 1995-08-09 | — | — | EP | claimed |
| CN-1100096-A | Process for the preparation of 2-{4-[4(4-chloro-1-pyrazolyl)butyl]1-piperazinyl} pyrimidine (lesopitron) | ENRIQUE MANOSAS BARRERA ATTORN (ES) | 1995-03-15 | — | — | CN | claimed |
| EP-0624585-A1 | Process for the preparation of 2-(4-(4-(4-chloro-1-pyrazolyl)butyl)1-piperazinyl)pyrimidine | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1994-11-17 | — | — | EP | claimed |
| EP-0429360-B1 | INHIBITION OF WITHDRAWAL SYNDROME | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1993-10-13 | — | — | EP | claimed |
| EP-0502786-A1 | Process for the preparation of aryl(or heteroaryl)-piperazin-1-butyl-azole derivatives | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 1992-09-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273600-A1 | LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF | SLC1A2, SLC6A5, SLC1A1 | HTR1A 151/4885DRD2 95/4885DRD3 67/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR1A 4/4885DRD2 345/4885DRD3 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.